Contributors: Institut Mondor de Recherche Biomédicale (IMRB); Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12); Service de psychiatrie; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier; Pôle de Psychiatrie Lille; Université Lille Nord (France)-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille); Université de Lille-Université de Lille; Fondation FondaMental Créteil; Pôle de psychiatrie; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal Paris; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); P.A. Geoffroy has received a prize from Bayer for being Laureate of the medical university of Lille. F. Bellivier has r eceived honoraria and financial support as an independent symposium speaker from Sanofi - Aventis, Lundbeck, AstraZeneca, Eli Lilly, Bristol - Myers Squibb and Servier. M. Leboyer has received honoraria and financial support as an independent symposium speaker from AstraZeneca and Servier. B. Etain has received honoraria and financial support as an independent symposium speaker from Sanofi - Aventis, Lundbeck, AstraZeneca, Eli Lilly, Bristol - Myers Squibb and Servier.
نبذة مختصرة : International audience ; Bipolar disorder (BD) is a severe chronic multifactorial disease that requires maintenance therapy with mood stabilizers (MS). Even with medications, the rate of response among patients with BD is low and the risk of relapse is high. Therefore, in this context of the urgent need for reliable and reproducible predictors of individual responses to MS, pharmacogenetics research is expected to provide helpful progress. Most pharmacogenetic studies of MS have focused on the response to lithium with several good putative candidate genes but informative results are sparse. There have been few studies on valproate, lamotrigine or atypical antipsychotics. Overall, the results of pharmacogenomics studies have not provided sufficient data to change daily practices in BD significantly and further investigation is warranted to identify highly relevant genetic predictors of response their roles. Although progress still remains to be made, the clinical assessment of a subject including the identification of specific individual phenotypic and pharmacogenetic characteristics is likely to become a powerful instrument for the development of personalized therapies.
Processing Request
No Comments.